ArticleBMC public health2026
Development and psychometric validation of a medication literacy scale for glucose-lowering therapy in Chinese adults with type 2 diabetes mellitus.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication literacy is essential for the safe and effective use of glucose-lowering therapies in adults with type 2 diabetes mellitus (T2DM). Existing instruments insufficiently capture the multidimensional competencies required for long-term medication management, and no validated tool is available for Chinese adults. This study aimed to develop and psychometrically validate the medication literacy scale for glucose-lowering therapy in adults with T2DM (MLSGT-T2DM) based on the Information–Motivation–Behavioral Skills (IMB) model.
methodsThe study was conducted from December 2024 to November 2025 and divided into three phases. Phase 1: An initial item pool was developed through a comprehensive literature review and semi-structured interviews with 18 patients with T2DM. Phase 2: Two rounds of Delphi expert consultation were conducted with 16 multidisciplinary experts, among whom 10 evaluated the content validity of the scale, and two rounds of cognitive interviews were carried out with 11 patients to assess face validity. Phase 3: The reliability of the scale was tested by internal consistency, split-half reliability, and retest reliability, and the validity of the scale was measured by exploratory factor analysis (EFA = 300) and confirmatory factor analysis (CFA = 276).
resultsEFA supported a six-factor structure nested within three IMB dimensions (information, motivation, behavioral skills). CFA confirmed good model fit (χ²/df = 2.264, CFI = 0.924, TLI = 0.914, RMSEA = 0.068, SRMR = 0.056). Convergent and discriminant validity were satisfactory. Reliability indices demonstrated strong internal consistency (Cronbach’s α = 0.902; McDonald’s ω = 0.904), acceptable split-half reliability (0.766), and high test–retest stability (ICC = 0.898). The final MLSGT-T2DM comprises 24 items.
conclusionThe MLSGT-T2DM is a psychometrically robust and theoretically grounded instrument for assessing glucose-lowering medication literacy among Chinese adults with T2DM. Its multidimensional structure enables precise identification of knowledge, motivational, and behavioral skill gaps, supporting targeted patient education and more effective diabetes self-management interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.